Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT-Sema: Brown Adipose Tissue as a Predictor of Semaglutide Response in Obesity
NCT07621640Not yet recruiting
- Sponsor
- Hallym University
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in obesity, sponsored by Hallym University. Primary endpoint: Correlation between baseline BAT metabolic activity and percentage body weight loss at 24 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07621640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621640.